General Catalyst Group Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MAZE
Maze Therapeutics
MAZE
|
+$12.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Warby Parker
WRBY
|
+$137M |
| 2 |
Vroom Inc
VRM
|
+$818K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 85.47% |
| 2 | Healthcare | 7.51% |
| 3 | Industrials | 3.8% |
| 4 | Consumer Discretionary | 3.19% |
| 5 | Financials | 0.03% |
Similar funds
General Catalyst Group Management's Q1 2025 Portfolio in Review
As of Q1 2025, General Catalyst Group Management held 12 positions worth $888M, down 22% from $1.14B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
General Catalyst Group Management withdrew a net $125M in Q1 2025, closing 1 position and reducing 1 holding. Its most notable exit was Warby Parker, an estimated $137M position sold in full.
By sector, the portfolio is most concentrated in Technology at 85% of assets, up from 76% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, General Catalyst Group Management opened a new position in Maze Therapeutics worth $11.4M.
- General Catalyst Group Management's largest Q1 2025 buy was Maze Therapeutics: 1,035,910 shares worth $11.4M.
- General Catalyst Group Management's biggest Q1 2025 reduction was Vroom Inc, cutting an estimated $818K.
- General Catalyst Group Management fully exited Warby Parker in Q1 2025, selling an estimated $137M.
- General Catalyst Group Management's ten largest holdings make up 100% of its $888M portfolio in Q1 2025.
- General Catalyst Group Management opened 1 new position and closed 1 in Q1 2025.
- General Catalyst Group Management's portfolio value fell 22% quarter-over-quarter to $888M.
Based on General Catalyst Group Management's 13F filing for Q1 2025, filed 16 Apr 2025.